ArticleBulletin of the World Health Organization2023
Cervical cancer screening aided by artificial intelligence, China.
Article in Bulletin of the World Health Organization, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Urban-rural disparities in HPV prevalence and genotype distribution: a large-scale cervical cancer screening study in Xi'an, China.BMC infectious diseases · 2026Article
- Artificial Intelligence in Cervical Cytology: Opportunities and Limitations in Screening, Triage, and Diagnostic Support.Diagnostics (Basel, Switzerland) · 2026Review
- Modelling the epidemic dynamics of HPV among women in China and optimization of ongoing cervical cancer elimination strategies.BMC medicine · 2026Article
- Factors Influencing Universal Coverage of AI-Assisted Cervical Cancer Screening: Qualitative Study Based on the Macro Model of Health System.Journal of medical Internet research · 2026Article
- KIF20A promotes cervical cancer progression by interacting with CLIP1.Scientific reports · 2026Article
- Artificial intelligence for colposcopic and cytological image analysis in early cervical cancer detection.iScience · 2026Review
- Artificial intelligence-driven screening, early diagnosis, and treatment strategies for cervical cancer: an overview.Infectious agents and cancer · 2025Review
- Advances in biomonitoring technologies for women's health.Nature communications · 2025Review
- Progress in the application research of cervical cancer screening developed by artificial intelligence in large populations.Discover oncology · 2025Review
- Risk factors for depression in patients in perimenopause with cervical cancer.World journal of psychiatry · 2025Article
- Review
- The Evolving Landscape of Cervical Cancer: Breakthroughs in Screening and Therapy Through Integrating Biotechnology and Artificial Intelligence.Molecular biotechnology · 2025Review
- Development, validation, and clinical application of a machine learning model for risk stratification and management of cervical cancer screening based on full-genotyping hrHPV test (SMART-HPV): a modelling study.The Lancet regional health. Western Pacific · 2025Article
- Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review.Frontiers in oncology · 2025Review
- Correlation analysis on risk factors for cervical cancer in perimenopausal women.American journal of translational research · 2025Article
- Performance of a Full-Coverage Cervical Cancer Screening Program Using on an Artificial Intelligence- and Cloud-Based Diagnostic System: Observational Study of an Ultralarge Population.Journal of medical Internet research · 2024Observational
- Utilization of artificial intelligence in clinical practice: A systematic review of China's experiences.Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To implement and evaluate a large-scale online cervical cancer screening programme in Hubei Province, China, supported by artificial intelligence and delivered by trained health workers. Methods: The screening programme, which started in 2017, used four types of health worker: sampling health workers, slide preparation technicians, diagnostic health workers and cytopathologists. Sampling health workers took samples from the women on site; slide preparation technicians prepared slides for liquid-based cytology; diagnostic health workers identified negative samples and classified positive samples based on the Bethesda System after cytological assessment using online artificial intelligence; and cytopathologists reviewed positive samples and signed reports of the results online. The programme used fully automated scanners, online artificial intelligence, an online screening management platform, and mobile telephone devices to provide screening services. We evaluated the sustainability, performance and cost of the programme. Results: From 2017 to 2021, 1 518 972 women in 16 cities in Hubei Province participated in the programme, of whom 1 474 788 (97.09%) had valid samples for the screening. Of the 86 648 women whose samples were positive, 30 486 required a biopsy but only 19 495 had one. The biopsy showed that 2785 women had precancerous lesions and 191 had invasive cancers. The cost of screening was 6.31 United States dollars (US$) per woman for the public payer: US$ 1.03 administrative costs and US$ 5.28 online screening costs. Conclusion: Cervical cancer screening using artificial intelligence in Hubei Province provided a low-cost, accessible and effective service, which will contribute to achieving universal cervical cancer screening coverage in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.